Detailed price information for Medicenna Therapeutics Corp (MDNA-T) from The Globe and Mail including charting and trades.

The appeals court for the Federal Circuit upheld a lower court’s ruling, finding that Regeneron has not sufficiently ...

Positive results from the pivotal ADEPT phase 2/3 study evaluating the investigational use of Dupixent (dupilumab) in adults with moderate-to-severe bullous pemphigoid (BP) were shared in a ...

Positive results from ADEPT phase 2/3 study of Dupixent in adults with moderate-to-severe bullous pemphigoid presented at AAD: Paris Tuesday, March 11, 2025, 14:00 Hrs [IST] Posit ...

The Dupixent development program has shown significant clinical benefit and a decrease in type 2 inflammation in phase 3 studies, establishing that IL4 and IL13 are two of the key and central drivers ...

The Dupixent development program has shown significant clinical benefit and a decrease in type 2 inflammation in phase 3 studies, establishing that IL4 and IL13 are two of the key and central ...

ATTO01310 targets IL31, while ATTO-002 hits both IL31 and IL13. The first clinical trial, of ATTO-002, is due to get underway next year. The financing was led by Goldman Sachs Alternatives ...

Total protein levels were correlated with CCL20, IL13, and basophil counts. Ninety-five shrimp proteins were identified, including seven known and eight potential allergens. Tropomyosin levels were ...

ABSTRACT: Introduction: Interstitial lung disease (ILD) is a progressive pulmonary disease, and many patients with ILD eventually require long-term oxygen therapy (LTOT) despite intensive treatment.

SubjectID type2_status 1 HR1005 type2_high2 HR1006 type2_high3 HR1009 type2_high4 HR1010 type2_high5 HR1012 type2_high6 HR1016 type2_high7 HR1038 type2_high8 HR1046 type2_high9 HR1065 type2_low10 ...